ASCO20: could a liquid biopsy guide prostate cancer treatment decisions?

Written by Rachel Jenkins, Future Science Group

Research presented at the American Society of Clinical Oncology (ASCO; 29–31 May 2020) virtual annual meeting has demonstrated the potential of a prostate cancer liquid biopsy for predicting treatment response. The results could help to advance oncology towards precision medicine by highlighting who is less likely to respond to treatment at the beginning, or who will relapse later on. The blood test, investigated by the Institute of Cancer Research (ICR; London, UK) and The Royal Marsden NHS Foundation Trust (London), could replace existing methods used to characterize and track the disease, such as tissue biopsies, as a blood test is...

To view this content, please register now for access

It's completely free